Exicure

Basketball players hands reaching for a ball near the hoop during a professional game
Biotech

Exicure scores in phase 2 multiple myeloma program

Since market open, Exicure’s stock has shot up 65%, rising from Friday’s close of $5.27 per share to $8.73 as of 10:10 a.m. ET today.
Gabrielle Masson Dec 9, 2025 10:15am
Three blocks displaying from left to right a person a handshake and another person

Exicure buys GPCR's US unit and clinical-stage blood cancer drug

Jan 23, 2025 5:01am
Magnifying glass search hunt business strategy

Exicure's CEO, CFO takes lead in search to bail out the biotech

May 30, 2023 8:30am
spiral stairs downward end dark black

Exicure considers transaction of some kind in death spiral

Mar 28, 2023 5:20am
Deal terminate tear up end deal scrap

AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure

Dec 14, 2022 7:15am
Graphic image of a graveyard with tombstones a full moon and a raven perched on a branch

The 2022 Biotech Graveyard

Nov 21, 2022 3:00am